You are here
Australian Adverse Drug Reactions Bulletin, Vol 20, No 1
Prepared by the Adverse Drug Reactions Advisory Committee (ADRAC) and the Office of Medicine Safety Monitoring (OMSM) of the TGA.
Since the introduction of celecoxib (Celebrex) to Australia in October 1999, ADRAC has received 2218 reports of suspected adverse drug reactions. Of these, there have been 21 cases describing an increase in the INR of patients on treatment with warfarin. In the 16 cases where the value of the INR was specified, it rose from a stable value of around 2.0 to a peak ranging from 4.2 to 12.2 (median: 5.3). In two other cases the INR was described as "high" and "very high". While most of the reports did not describe complications, bleeding was reported in 6 cases. These included severe oral bleeding, intracranial haemorrhage, epistaxis and gastrointestinal haemorrhages. In most cases, the problem occurred within two weeks of the addition of celecoxib. Of the patients in whom the outcome was known, all recovered after withdrawal of celecoxib and in some cases, withholding or reducing the dose of warfarin.
In addition to these 21 cases, there have been 11 cases of bleeding in patients taking concomitant celecoxib and warfarin. These reports described purpura (3 cases), gastrointestinal haemorrhage (2), haematuria (1), haematemesis (1), melaena (1), subdural haematoma (1), unspecified haemorrhage (1) and a stroke (1). There was no reference to the INR in these reports except for one in which the INR was reported as unchanged. It is not clear in these cases whether the bleeding was the result of an interaction, an additive effect, an effect of celecoxib alone, or unrelated to the use of celecoxib.
The product information for celecoxib states that in postmarketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving celecoxib concurrently with warfarin. In the cases of increased INR and bleeding reported to ADRAC, 5 of the 26 patients in whom the age was stated were aged less then 50 years.
The product information also describes a study in healthy volunteer subjects given 2 mg to 5 mg warfarin daily in whom celecoxib had no effect on the prothrombin time. However, since warfarin is metabolised mainly by CYP2C9 and this enzyme can be inhibited by celecoxib, it is possible that in some individuals, inhibition of CYP2C9 may be significant, producing higher blood concentrations of warfarin. There have been two recent publications describing this interaction.1,2
- Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34: 325-7.
- Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between warfarin and celecoxib. Ann Pharmacother 2000; 34: 666-7.
At a recent ADRAC meeting, members reviewed 4 reports which described lactic acidosis in association with metformin. These reports serve as a reminder that this well-known reaction is still occurring in the community and care needs to be taken to avoid it. Lactic acidosis with metformin has considerable morbidity, and mortality has been estimated to be about 50%. A review of cases reported to the United States Food and Drug Administration indicated that 43 of 47 patients had one or more risk factors for lactic acidosis.1 These include preexisting cardiac disease or renal insufficiency, chronic pulmonary disease, severe liver disease and age over 80 years. Another risk factor is believed to be raised plasma metformin concentrations due to high dose or accumulation of the drug in the presence of impaired renal function. It is recommended that metformin be withheld 24 hours before surgery, radiological procedures with contrast or other invasive procedures.
In Australia, there have been 48 reports to ADRAC of lactic acidosis with metformin. The outcome was fatal in 15 cases. Of the 48 cases, known risk factors were identified in 35.
The product information for metformin contains the following highlighted warning:
Life-threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age and high doses of metformin (> 2 g/day).
- Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265-6.
Cerivastatin (Lipobay) is the fifth of the HMG-CoA reductase inhibitors ("statins") to be marketed in Australia. Rhabdomyolysis is a known but rare effect of all the statins and is more likely to occur when a fibrate is taken concurrently. Its occurrence in association with cerivastatin appears greater than with other statins. To January 2001 ADRAC has received a total of 95 reports with cerivastatin, of which 17 (18%) have described rhabdomyolysis. This can be compared with the other statins for which the percentages range from 0.3 to 1.2%.
The 17 cases of rhabdomyolysis with cerivastatin occurred from just over a week to 18 months after the introduction of cerivastatin but most occurred in the first month of therapy. Seven of the 15 cases in which the dose was stated occurred with daily dosages of 400 µg or greater and two cases occurred shortly after the dose was increased to 800 µg daily.
Of particular interest is the fact that ten of the 17 patients were taking gemfibrozil concomitantly. The sponsor has made the concomitant use of cerivastatin and gemfibrozil a contraindication.
ADRAC wishes to alert prescribers to the possibility of rhabdomyolysis with all statins. Cerivastatin should not be used in combination with gemfibrozil.
|Drug||No. of Reports|
From November 1972 to January 2001 ADRAC has received 92 reports of raised intraocular pressure. Since 1992, there have been 11 reports implicating selective serotonin reuptake inhibitors (SSRIs) involving sertraline (4 reports), fluoxetine (3), paroxetine (3) and citalopram (1). Ages of the patients in these reports ranged from 32 to 70 years. Onset generally occurred within 6 months of commencing the SSRI but ranged from one week to 5 years. In two cases, the SSRI may have aggravated pre-existing glaucoma. In one case, the intraocular pressures which had previously been stabilised with treatment, almost doubled. Presentations consisted of asymptomatic increases in intraocular pressures noted on routine testing (6 cases), eye pain (2 cases), and blurred vision (3 cases). At the time of reporting, 5 patients had not recovered and the outcome remained unknown for the other 6.
The major causes of raised intraocular pressure reported to ADRAC are shown in the Table with corticosteroids, antidepressants and mydriatics accounting for more than half of the reports. The association with SSRIs is less well known and is probably very uncommon although there have been several published case reports.
The names of the wide range of insulin products can cause confusion. The most recent example concerns the possibility for confusion between Humalog and Humalog Mix25.
Humalog is the product name for lispro insulin, a fast acting analog of human insulin. Humalog Mix25 contains 25% lispro insulin and 75% lispro insulin protamine suspension. ADRAC has been notified of a small number of instances where the similarity of the two product names has led to dispensing or have been reported but the potential for harm is clear.
Prescribers and dispensers need to be aware of the potential for confusion. Humalog is a clear, rapidly acting insulin. Humalog Mix25 is cloudy and combines rapid with intermediate actions. The sponsor, Eli Lilly, is aware of the problem and has distributed educational material to health professionals. It also intends to soon amend the packaging of the products to help differentiate the two insulins.
Please report all suspected reactions to these Drugs of Current Interest
- Bupropion (Zyban)
- Candesartan (Atacand)
- Celecoxib (Celebrex)
- Clopidogrel (Iscover, Plavix)
- Eprosartan (Teveten)
- Gelatin succinylated (Gelofusine)
- Leflunomide (Arava)
- Naltrexone (ReVia)
- Orlistat (Xenical)
- Quetiapine (Seroquel)
- Raloxifene (Evista)
- Repaglinide (NovoNorm)
- Rivastigmine (Exelon)
- Rofecoxib (Vioxx)
- Rosiglitazone (Avandia)
- Sildenafil (Viagra)
- Telmisartan (Micardis/Pritor)
- Tibolone (Livial)
- Tramadol (Tramal)
- Zolpidem (Stilnox)
(you do not need to be certain, just suspicious!)
ADRAC encourages the reporting of all suspected adverse reactions to medicines, including vaccines, OTC medicines, herbal, traditional or alternative remedies. ADRAC particularly requests reports of:
- ALL suspected reactions to new drugs (see drugs of current interest)
- ALL suspected drug interactions
- Suspected reactions causing
- Admission to hospital or prolongation of hospitalisation
- Increased investigations or treatment
- Birth defects
For blue cards
Reports of suspected adverse drug reactions are best made by using a prepaid reporting form ("blue card") which is available from the website or from the Office of Medicines Safety Monitoring (02 6232 8744).
Reports can also be submitted electronically, by clicking on "Report a problem" on this website, by fax: 02 6232 8392, or email: ADR.Reports@tga.gov.au.
© Commonwealth of Australia 2001
All correspondence to be addressed to: The Secretary, ADRAC, PO Box 100, Woden ACT 2606